A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
← catalyst calendarNCT07272642 · readout in 376 d
Sponsored by Radiopharm Theranostics, Ltd (industry) · RADX — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
16estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-30 | estimated | When the study began enrolling |
| Primary completion | 2027-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Imaging
- Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma
- Non-Small Cell Lung Cancer
- Triple Negative Breast Cancer (TNBC)
Intervention
- Drug: LNTH-2403
Primary outcome
what the primary-completion date above is the date OFTo assess the safety and tolerability of a single dose of LNTH-2403
measured 90 days
Permalink · RADX's whole pipeline · Catalyst calendar · Every registered study · What changed